But appointment unlikely to signal new emphasis on prescription drugs for MedCAC.
The new chairman of the Medicare Evidence Development and Coverage Advisory Committee is Peter Bach, director of the Center for Health Policy and Outcomes at the Memorial Sloan-Kettering Cancer Center, and a noted critic of oncology drug prices.
He disclosed his appointment on Twitter Sept. 4
No mass exodus was seen from stand-alone prescription drug plans to Medicare Advantage drug plans between 2024 and 2025, according to one actuary.
Mechanisms in the draft treaty that the more than 190 member states of the World Health Organization have finally agreed to are expected to “materially affect companies,” particularly those that develop, manufacture or distribute pandemic-related health care products.
The preliminary budget document supports legislation clawing back funds appropriated for the program.
